Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 9 of 9 results for erenumab

  1. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

  2. Eptinezumab for preventing migraine (TA871)

    Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

  3. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

  4. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

  5. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  6. Past appeals and decisions

    TA076 Epilepsy (adults) - newer drugs 19 January 2004 TBC Erenumab for treating migraine 4 December 2019 TA854 Esketamine for...

  7. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  8. 145,000 people in England to have further treatment choice for preventing migraine attacks.

    NICE has for the first time recommended an oral treatment for preventing migraines.

  9. Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine

    NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.